Retatrutide 30 MG
$224.99
In stockRetatrutide is an investigational peptide that activates three hormone receptors: GLP-1, GIP, and glucagon. This “triple-agonist” activity is being studied for its effects on body weight, blood-glucose regulation, and obesity-related conditions. Clinical trials have evaluated it as a once-weekly subcutaneous injection.
| SKU | RC-ST-RETA-30MG |
|---|---|
| Manufacturer | Strandix Peptides |
| Form | Lyophilized Powder |
| Strength | 30 mg |
| Size | 3 mL Vial |
| Reported Result | See matching batch report |
| Stock | In stock |
| Documentation Status | Client-supplied report available |
Product Description
Retatrutide is an investigational peptide that activates three hormone receptors: GLP-1, GIP, and glucagon. This “triple-agonist” activity is being studied for its effects on body weight, blood-glucose regulation, and obesity-related conditions. Clinical trials have evaluated it as a once-weekly subcutaneous injection.
What research has shown:
Substantial weight loss in adults without diabetes: In the phase III TRIUMPH-1 trial involving 2,339 participants, average weight reduction at 80 weeks reached 25.0% in the highest-dose group, compared with 3.9% with placebo. These are group averages from a controlled trial, rather than guaranteed individual results.
Weight loss in adults with type 2 diabetes: The phase III TRIUMPH-2 trial reported average weight reductions of 18.8% in the highest-dose group, compared with 5.1% with placebo, at 80 weeks.
Improved blood-glucose control: TRIUMPH-2 also reported improvements in glycemic control, supporting continued investigation of retatrutide for people with obesity and type 2 diabetes.
Storage and handling: Keep unopened lyophilized material sealed, protected from light and moisture, and stored at the temperature specified by the manufacturer. Confirm sequence, counterion, assay, purity, water content, and stability on the COA. Do not publish reconstitution or administration instructions.
.png)